[
    "{\"step_by_step_thinking\": \"Based on the provided documents, Algenpantucel-L immunotherapy has shown promise in the treatment of pancreatic cancer. Document [1] reports the results of a phase II study where patients with resected pancreatic cancer received gemcitabine and 5-fluorouracil-based chemoradiotherapy along with Algenpantucel-L. The study found that the addition of Algenpantucel-L to standard adjuvant therapy improved survival. Document [4] mentions a phase 3 trial (NCT01836432) evaluating the efficacy and safety of Algenpantucel-L immunotherapy in patients with borderline resectable or locally advanced unresectable pancreatic cancer. Although the results of this trial are not mentioned, it indicates ongoing research on the use of Algenpantucel-L in pancreatic cancer. Therefore, based on the available evidence, the answer is A. yes.\", \"answer_choice\": \"A\"}"
]